Associated tags: Immune system, IND, HIE, European Medicines Agency, Peptide, Food, Research, Hypoxia (medical), Virus, Health, Clinical Trials, Science, Pharmaceutical industry, Pharmaceutical, Biotechnology, Other Science, Doctor of Philosophy, Patient, Safety, Rodels-Realta railway station, General Health, MD, Neutrophil extracellular traps
Locations: NEW YORK, ARDS, UNITED STATES, NORTH AMERICA, VIRGINIA, RARE, PUERTO RICO
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Radiation,
Acute radiation syndrome,
Attack,
ARS,
Inflammation,
Education,
Chronic obstructive pulmonary disease,
RNCP,
USUHS,
Virus,
IND,
European Medicines Agency,
Outline of health sciences,
Nausea,
Accident,
Hypoxia (medical),
NIAID,
Defense Threat Reduction Agency,
AFRRI,
HIE,
Vaccine,
Collection,
Vomiting,
Food,
FDA,
Defense,
Infection,
Peptide,
Pharmaceutical industry “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
Key Points:
- “We are very pleased to partner with NIAID and AFRRI to evaluate ReAlta’s lead drug candidate, RLS-0071, as a radiation countermeasure for GI-ARS,” says Dr. Ulrich Thienel, Chief Executive Officer of ReAlta.
- AFRRI is unique and powerful radiobiological research institute, with six decades of active, robust, and outstanding support to the U.S. Department of Defense through research, reach-back, and education.
- It is the only U. S. Department of Defense medical R&D facility dedicated solely to nuclear and radiological defense.
- ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life threatening acute inflammatory and rare diseases.
Retrieved on:
Wednesday, February 21, 2024
Health,
Other Science,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Inflammation,
Chronic obstructive pulmonary disease,
Safety,
Hypoxia (medical),
Biomarker,
Pharmacokinetics,
Patient,
MPH,
Disease,
COPD,
Neutrophil extracellular traps,
Pharmaceutical industry RLS-0071 is the Company’s lead dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation and is currently in development for the treatment for hypoxic ischemic encephalopathy, acute graft-versus-host disease, and other rare and acute inflammatory diseases.
Key Points:
- RLS-0071 is the Company’s lead dual-targeting peptide that uniquely inhibits both complement and neutrophil-associated inflammation and is currently in development for the treatment for hypoxic ischemic encephalopathy, acute graft-versus-host disease, and other rare and acute inflammatory diseases.
- The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial to evaluate safety, pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of RLS-0071 in patients with acute exacerbations of chronic obstructive pulmonary disease.
- Approximately 24 hospitalized patients will receive doses of either RLS-0071 or placebo in addition to standard of care treatment for up to five days.
- Key secondary endpoints include biomarkers of inflammation, physiological response to RLS-0071 compared to placebo, as well as clinical progression and resolution.
Retrieved on:
Wednesday, January 24, 2024
Research,
Clinical Trials,
Health Technology,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Artificial intelligence,
NSRI,
University,
Patient,
Principal,
Executive Committee,
UARC,
Government,
JHUAPL,
Partnership,
Containerization,
Epigenome,
GSK,
Diagnosis,
DTRA,
Drug discovery,
Chemical engineering,
COVID-19,
Applied Physics Laboratory,
Biomedical engineering,
CBCS,
Department of Defence,
DARPA,
Therapy,
Doctor of Philosophy,
Traumatic brain injury,
Nursing care plan,
Machine learning,
Pennsylvania State University,
STRATCOM,
MRIGlobal,
SVP,
ARA,
Medical device “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
Key Points:
- “We are delighted to welcome Dr. Baldoni and Dr. Van Gieson to our Board of Directors and look forward to their expertise as we continue to advance our EPICC platform beyond our current portfolio,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors.
- Dr. Baldoni’s Platform Technology and Science team supported the development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization.
- Dr. Baldoni stepped away from that leadership role in 2017 to start the first AI-driven drug discovery unit at GSK.
- After retiring from GSK in 2019, he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discovery startup.
Retrieved on:
Wednesday, January 3, 2024
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Clinical Trials,
Kite Pharma,
Engineering management,
Tufts University,
Marketing,
Lilly,
Migraine,
Johnson & Johnson,
Amgen,
Sale,
AstraZeneca,
Daiichi Sankyo,
Eli Lilly,
Jan Vansina,
Business administration,
Engineering,
WebMD,
MBA,
Chemical engineering,
Doctor of Philosophy,
Roivant Sciences,
Therapy,
Eli Lilly and Company,
Consumer service,
University,
Washington State University,
Worcester Polytechnic Institute,
Iowa State University,
SVP,
Corporation,
Pharmaceutical industry ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
Key Points:
- ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.
- “We are delighted to welcome Christi Shaw, Mert Aktar and David Marek, and the tremendous expertise and wise counsel they represent, to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta's Board of Directors.
- Prior to Kite, Ms. Shaw served as an executive officer of Eli Lilly and Company (Lilly), a global healthcare company, and president of Lilly Bio-Medicines.
- Mr. Aktar is an accomplished life sciences industry executive with over twenty years of multinational experience bridging science and business in pharmaceuticals and biotechnology.
Retrieved on:
Tuesday, October 24, 2023
Research,
FDA,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Patient,
IND,
Food,
Biomarker,
Hypoxia (medical),
Investigational New Drug,
MD,
HIE,
Rodels-Realta railway station,
Doctor of Philosophy,
Inflammation,
Quality of life,
System,
Immune system,
Risk,
Genetically modified bacteria,
Safety,
Hospital,
AE,
Food and Drug Administration,
Chronic obstructive pulmonary disease,
Death,
COPD,
Neutrophil extracellular traps,
Pharmaceutical industry RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for AE-COPD, acute graft-versus-host disease (aGvHD), hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.
Key Points:
- RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for AE-COPD, acute graft-versus-host disease (aGvHD), hypoxic-ischemic encephalopathy (HIE), and other rare and acute inflammatory diseases.
- “Patients with chronic obstructive pulmonary disease (COPD) face the persistent threat of hospitalization, mechanical ventilation and death from an acute exacerbation, an acute worsening of symptoms triggered by a viral or bacterial infection, or environmental irritant.
- “This FDA clearance marks an important new milestone for ReAlta as we explore the potential of RLS-0071 across multiple therapeutic areas."
- The Phase 2 clinical trial will be a randomized, double-blind, placebo-controlled trial in hospitalized patients with AE-COPD.
Retrieved on:
Thursday, October 12, 2023
Biotechnology,
White House,
Federal Government,
Health,
Healthcare Reform,
Pharmaceutical,
Other Policy Issues,
Other Science,
Research,
Public Policy,
Government,
Science,
Clinical Trials,
Multimedia,
Chief Management Officer of the Department of Defense,
Doctor of Philosophy,
CSO,
Asphyxia,
COVID,
Sepsis,
MD,
Graft-versus-host disease,
Warner,
United States Senate Select Committee on Nutrition and Human Needs,
HIE,
CMO,
Hypoxia (medical),
Rodels-Realta railway station,
Immune system,
Military personnel,
Senator Warner,
Acute radiation syndrome,
BARDA,
Patient,
United States Senate Select Committee on Intelligence,
Pharmaceutical industry,
Intelligence ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
Key Points:
- ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the power of the immune system to address life-threatening diseases, was pleased to welcome Senator Mark R. Warner (D-Va) for an in-depth visit with the ReAlta management team, members of the ReAlta board of directors, and local investors on October 2, 2023.
- View the full release here: https://www.businesswire.com/news/home/20231012073021/en/
Sen. Mark Warner (D-Va) with ReAlta CEO Dr. Ulrich Thienel, board chairman Edward Heidt, Jr., CMO Dr. Kenji Cunnion, CSO Dr. Neel Krishna, and ReAlta staff.
- “ReAlta is on the cutting edge of research in a variety of fronts – from COVID to birth asphyxia,” said Sen. Mark R. Warner.
- The company looks forward to continuing to push the boundaries of what is possible in the fight against life-threatening rare diseases.
Retrieved on:
Wednesday, September 6, 2023
Sports,
General Sports,
Biotechnology,
FDA,
Health,
Pharmaceutical,
Other Science,
Research,
Infectious Diseases,
Science,
Clinical Trials,
Graft-versus-host disease,
Investigational New Drug,
HIE,
Food and Drug Administration,
Pharmacokinetics,
Rodels-Realta railway station,
Biomarker,
Inflammation,
Doctor of Philosophy,
System,
Chronic endothelial injury hypothesis,
MD,
Patient,
Immune system,
Neutrophil extracellular traps,
IND,
Food,
Safety,
Hypoxia (medical),
Pharmaceutical industry “In steroid-refractory patients, acute Graft-versus-Host Disease is driven by endothelial injury followed by neutrophil recruitment and activation, NETosis and complement activation.
Key Points:
- “In steroid-refractory patients, acute Graft-versus-Host Disease is driven by endothelial injury followed by neutrophil recruitment and activation, NETosis and complement activation.
- This underlying pathogenesis has a devastating impact on patients with steroid-refractory acute GvHD and calls for innovative and effective treatments.
- “This FDA clearance marks an important new milestone for ReAlta as we explore the potential of RLS-0071 across multiple indications."
- The Phase 2 clinical trial will be an open label, prospective dose-ranging study with escalation and expansion cohorts to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, dosing and efficacy in hospitalized patients with steroid-refractory acute Graft-versus-Host Disease.
Retrieved on:
Tuesday, September 5, 2023
Research,
Infectious Diseases,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
European Respiratory Society,
Human,
Protocol,
Reactive airway disease,
Toxicology,
Hypoxia (medical),
Medical research,
Immune system,
Fraunhofer Society,
Rare,
International Congress on Tuberculosis,
POM,
White lung,
Pharmaceutical industry ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
Key Points:
- ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
- RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other acute inflammatory and rare diseases.
- The new data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine (Hannover, Germany) and lead investigator on the Phase 1b trial.
- Session 68 (PA608) – From bench to bedside: translational studies in airway diseases
Health,
Neurology,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
COPD,
Graft-versus-host disease,
Medicine,
Doctor of Philosophy,
STAR,
Pharmacokinetics,
HIE,
C1,
Oxygen,
Hypothermia,
Brain,
DSM-IV codes,
Rodels-Realta railway station,
Asphyxia,
Key Stage 1,
Hypoxia (medical),
Patient,
MPO,
Immune system,
Neutrophil extracellular traps,
Observation,
Mortality,
MPH,
Death,
Disease,
Pharmaceutical industry,
Safety,
MD,
Infant ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune system, today announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns.
Key Points:
- ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune system, today announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns.
- After completion of Stage 1, participants will transition to Stage 2 of the study for long-term observation out to 24 months of age.
- The initial loss of oxygen and the dysregulated inflammatory process that follows causes damage to the brain and other organs.
- This acute disease often results in death or moderate-to-severe cognitive and physical disability, with life-long impacts on both the newborn and the newborn’s family.
Health,
Other Science,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Member of Congress,
Graft-versus-host disease,
Learning,
Multimedia,
Rodels-Realta railway station,
Doctor of Philosophy,
MD,
Patient,
Immune system,
Economic development,
Peptide,
Hypoxia (medical),
Tourism,
Management,
Pharmaceutical industry Key Points:
- View the full release here: https://www.businesswire.com/news/home/20230727405779/en/
Congressman Bobby Scott visiting with ReAlta CEO Dr. Ulrich Thienel and staff.
- (Photo: Business Wire)
Congressman Scott, a long-standing advocate for healthcare innovation and economic development, took a keen interest in learning about the work done at ReAlta.
- During the visit, Congressman Scott toured ReAlta’s research laboratory, during which he observed first-hand the advanced research conducted by ReAlta scientists to develop innovative new EPICC peptides and translate research insights into new therapies for the clinic.
- “Thank you to Dr. Thienel and the entire team at ReAlta Life Sciences for hosting me for a tour and briefing,” said Congressman Bobby Scott.
